CD19 and acute lymphoblastic leukemia: The first FDA approvals were witnessed in 2017, with Kymriah® (Novartis, Basel, Switzerland) and Yescarta® (Kite Pharma, Santa Monica, CA, USA) targeting the B cell antigen CD19 to treat B-acute lymphocytic leukemia (B-ALL) and DLBCL, respectively.